Xopenex Hfa

Hyperkalemia, Acute Bronchitis, Pneumonia + 18 more

Treatment

9 FDA approvals

20 Active Studies for Xopenex Hfa

Treatment for

Hyperkalemia

What is Xopenex Hfa

Salbutamol

The Generic name of this drug

Treatment Summary

Levosalbutamol, also known as levalbuterol, is an inhalable medication used to treat asthma and chronic obstructive pulmonary disease (COPD). It is a short-acting form of salbutamol, which is a racemic mixture of two forms of the same drug. Levosalbutamol is an enantiomerically pure formulation of the active (R)-form of salbutamol, which has been found to have fewer side effects than the (S)-form.

Proair HFA

is the brand name

image of different drug pills on a surface

Xopenex Hfa Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Proair HFA

Salbutamol

1981

314

Approved as Treatment by the FDA

Salbutamol, also known as Proair HFA, is approved by the FDA for 9 uses like prophylaxis of Exercise-induced bronchospasm and prophylaxis of Bronchospasm .

prophylaxis of Exercise-induced bronchospasm

prophylaxis of Bronchospasm

Bronchospasm, Exercise-Induced

Bronchial Spasm

Asthma, Exercise-Induced

Chronic Obstructive Pulmonary Disease

Used to treat Chronic Obstructive Pulmonary Disease (COPD) in combination with Ipratropium

Bronchodilator Agents

Used to treat need of more than one bronchodilator in combination with Ipratropium

Exercise-Induced Bronchospasm

Bronchospasm

Effectiveness

How Xopenex Hfa Affects Patients

This drug helps to open up the airways in the lungs, making it easier to breathe and relieving shortness of breath.

How Xopenex Hfa works in the body

Levosalbutamol works by affecting the β2 adrenergic receptors in your airway smooth muscle. When activated, these receptors increase the amount of cyclic AMP in your cells. The increased cyclic AMP causes a decrease in the ionic calcium concentrations of your muscles, making them relax. It also stops the release of mediators from mast cells in your airways, which helps ease asthma attacks.

When to interrupt dosage

The prescribed dosage of Xopenex Hfa depends on the determined condition, including Chronic Obstructive Pulmonary Disease (COPD), Bronchospasm and prophylaxis of Bronchospasm. The amount of dosage fluctuates as per the delivery approach (e.g. Respiratory (inhalation) or Oral) delineated in the table beneath.

Condition

Dosage

Administration

Acute Bronchitis

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Solution - Nasal, Solution - Intravenous, Intravenous, Liquid - Intravenous, Inhalant - Nasal

Bronchial Spasm

Emphysema

Asthma

Influenza

Bronchodilation

Bronchodilator Agents

Asthma

Bronchitis

Bronchitis, Chronic

Asthma, Exercise-Induced

prophylaxis of Bronchospasm

excess mucus or phlegm

Hyperkalemia

Pneumonia

Respiratory Tract Infections

Asthma

Airway secretion clearance therapy

Bronchospasm, Exercise-Induced

Chronic Obstructive Pulmonary Disease

Warnings

There are 20 known major drug interactions with Xopenex Hfa.

Common Xopenex Hfa Drug Interactions

Drug Name

Risk Level

Description

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Hydroxyzine.

Mobocertinib

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mobocertinib.

Ziprasidone

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ziprasidone.

1-benzylimidazole

Minor

The risk or severity of hypertension can be increased when Salbutamol is combined with 1-benzylimidazole.

2,5-Dimethoxy-4-ethylamphetamine

Minor

The risk or severity of hypertension can be increased when Salbutamol is combined with 2,5-Dimethoxy-4-ethylamphetamine.

image of a doctor in a lab doing drug, clinical research

Xopenex Hfa Novel Uses: Which Conditions Have a Clinical Trial Featuring Xopenex Hfa?

98 active clinical trials are currently being conducted to assess the effectiveness of Xopenex HFA in prophylaxis of Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD) and Bronchial Spasm.

Condition

Clinical Trials

Trial Phases

Bronchospasm, Exercise-Induced

0 Actively Recruiting

Chronic Obstructive Pulmonary Disease

70 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Asthma

87 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Not Applicable, Phase 2, Phase 3

prophylaxis of Bronchospasm

0 Actively Recruiting

Influenza

28 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3

Hyperkalemia

4 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1

Bronchitis, Chronic

0 Actively Recruiting

excess mucus or phlegm

0 Actively Recruiting

Bronchodilator Agents

0 Actively Recruiting

Pneumonia

17 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2, Phase 4

Bronchial Spasm

0 Actively Recruiting

Asthma

1 Actively Recruiting

Phase 2

Airway secretion clearance therapy

0 Actively Recruiting

Respiratory Sounds

4 Actively Recruiting

Phase 2, Phase 3

Asthma

1 Actively Recruiting

Phase 4

Asthma, Exercise-Induced

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Bronchitis

0 Actively Recruiting

Acute Bronchitis

8 Actively Recruiting

Phase 4, Not Applicable, Phase 3, Early Phase 1

Bronchodilation

0 Actively Recruiting

Xopenex Hfa Reviews: What are patients saying about Xopenex Hfa?

Patient Review

12/12/2012

Xopenex Hfa for Asthma Attack

Xopenex HFA is the only inhaler that has helped me to get rid of mucus from my lungs. I have been using it for three months and have noticed some blurred vision and occasional slight dizziness.

Patient Review

8/28/2010

Xopenex Hfa for Asthma Attack

Xopenex has been much more effective for me than Proventil. With the latter, I needed two or three puffs to get full relief, but Xopenex only requires one puff. The only downside is that it sometimes makes me feel jittery.

Patient Review

4/6/2011

Xopenex Hfa for Bronchospasm

I love this stuff! I used to use Albuterol, but I would get jittery and have to take 4-6 puffs of it to feel relief. With Xopenex HFA, I only need one or two puffs.

Patient Review

8/1/2016

Xopenex Hfa for Asthma Attack

This medication is much more effective than Albuterol.

Patient Review

8/18/2016

Xopenex Hfa for Asthma Attack

This medication is much more effective for me than Albuterol.

4.7

Patient Review

7/24/2012

Xopenex Hfa for Bronchospasm Prevention

No rapid heart rate; works with one puff right before I exercise. Great drug - much better than ventolin

4.3

Patient Review

10/26/2009

Xopenex Hfa for Asthma Attack

I was pleased with this treatment for my asthma. I was prescribed both an inhaler and a nebulizer, and the shaking has gone away. My only complaint is that it doesn't seem to work as well when I'm running.

4.3

Patient Review

1/6/2010

Xopenex Hfa for Asthma Attack

I find this inhaler effective, though it has the unfortunate side effect of making me cough. If anyone else has experienced this, please let me know.

4.3

Patient Review

9/24/2009

Xopenex Hfa for Asthma Attack

I appreciate that this drug doesn't make me nauseous or jittery.

Patient Review

3/30/2009

Xopenex Hfa for Asthma Attack

Since my allergist switched me from Albuterol to Xopenex HFA, I've noticed that when I have attacks, recovery takes longer and is less effective.

Patient Review

3/16/2010

Xopenex Hfa for Osteoporosis

This treatment really helped me. I'm grateful for modern medicine.

2.3

Patient Review

3/22/2009

Xopenex Hfa for Bronchospasm

Unfortunately, I experienced some very unpleasant side effects from this drug. Dizziness and a pounding headache set in within two hours of inhaling the medication, and unfortunately these symptoms persisted even after taking another dose. This treatment did not provide any relief from my breathing difficulties.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about xopenex hfa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Xopenex HFA used for?

"It works by relaxing and opening air passages in the lungs to make breathing easier.

Levalbuterol treats and prevents wheezing and shortness of breath caused by breathing problems such as asthma and COPD. It works by relaxing and opening air passages in the lungs to make breathing easier."

Answered by AI

Is Xopenex HFA the same as albuterol?

"Albuterol and Xopenex are both drugs with similar actions that are offered in different forms. Albuterol is available as an inhalant, oral tablet, and oral syrup, while Xopenex is only offered in an inhaled form. The cost of both drugs is similar, with generic versions of both now available."

Answered by AI

Is Xopenex HFA a rescue inhaler?

"Unlike other inhalers, Xopenex HFA can be used to relieve bronchospasm caused by exercise.

Xopenex HFA is a quick-acting inhaler that is used to treat bronchospasm. It works by relaxing the muscles around the airways to make breathing easier. Xopenex HFA can be used to relieve bronchospasm caused by exercise."

Answered by AI

Is Xopenex HFA a steroid?

"No, Xopenex (levalbuterol) is not a steroid. Xopenex (levalbuterol) is a bronchodilator, which relaxes the muscles in your lungs. Steroids are also used in asthma to lower inflammation in your lungs. These two types of medications work well together to help you breathe, but they are not the same thing."

Answered by AI

Clinical Trials for Xopenex Hfa

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17

All Sexes

Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4

Waitlist Available

New This Month

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Xopenex Hfa clinical trials?

We made a collection of clinical trials featuring Xopenex Hfa, we think they might fit your search criteria.

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions

Have you considered Xopenex Hfa clinical trials?

We made a collection of clinical trials featuring Xopenex Hfa, we think they might fit your search criteria.

Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+

All Sexes

Nashville, TN

This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?

Phase 2

Recruiting

Has No Placebo

Vanderbilt University Medical Center

Natahsa Halasa, MD, MPH